Skip to main content
Premium Trial:

Request an Annual Quote

Acacia to Spin Out CombiMatrix as Independent Public Company

NEW YORK, Jan. 9 (GenomeWeb News) - Acacia Research said today that its board of directors has approved a plan for its CombiMatrix microarray subsidiary to become an independent public company.


Acacia said it expects the transaction to close in the second quarter of 2006, subject to receiving a "satisfactory tax opinion from legal counsel" and other conditions.


If these conditions are met, Acacia will redeem all of the issued and outstanding shares of Acacia Research-CombiMatrix common stock, which trades under the ticker symbol CBMX, for all of the common stock of CombiMatrix, which will list its shares for trading on Nasdaq.


The spin-out "will benefit both companies by eliminating the risk factors associated with the current capital structure," Paul Ryan, chairman and CEO of Acacia, said in statement. The separation of the two companies is also expected to make the firms more attractive to investors, he said.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.